Agendia COVID-19 Statement

March 18, 2020

As a valued customer we wanted to reach out and assure you that we are monitoring the situation regarding the outbreak of Corona Virus Disease (COVID-19) very closely; your patient’s sample and the safety of our staff is our highest priority. We are taking every measure to ensure the continued timely and high-quality handling of…

Read more

Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer

February 18, 2020

PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 13, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that BMC Cancer published results from the IMPACt…

Read more

Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020

January 17, 2020

PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 17 January 2020 – Laura van ‘t Veer, Ph.D., co-founder of Agendia Inc. and developer of MammaPrint, the 70-gene risk of recurrence assay for breast…

Read more

Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse

January 3, 2020

PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse   IRVINE, CALIF., U.S. and Amsterdam – 3 January 2020 – Agendia Inc., a world leader in precision oncology for breast cancer, announces that one of the largest healthcare insurers in Germany, Techniker Krankenkasse, has joined the Selective…

Read more